Janux Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
About Janux Therapeutics
Pharmaceutical Preparations, SIC 2834
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune conditions. The company utilizes its proprietary TRACTr, TRACIr, and ARM technology platforms to create engineered bispecific molecules and T cell engagers. Its main clinical-stage candidates include JANX007, an investigational TRACTr therapy designed to treat metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeting TRACTr being evaluated across various solid tumor indications. In addition, the firm is advancing JANX011 for autoimmune diseases. While its clinical candidates are designed to treat patients, the company also engages with large biopharmaceutical collaborators such as Merck Sharp & Dohme and Bristol Myers Squibb.
The company's pipeline assets undergo clinical and nonclinical evaluation across multiple study cohorts and indications, though the text does not disclose operational metrics, facility counts, geographic footprints, or the location of its corporate headquarters.
Summary of the business section of Janux Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Janux Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10955 Vista Sorrento Parkway, Suite 200 92130
- Phone
- (858) 751-4493
- Employees
- 109, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- JANX
- Exchange
- Nasdaq
- IPO date
- Jun 11, 2021
- Shares outstanding
- 61M, Aug 4, 2026
- Public float
- $1.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1817713
- CUSIP
- 47103J105
- ISIN
- US47103J1051
- EIN
- 82-2289112
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Alan Campbell | President and CEO, Director | 264,742 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 |
| Maria Dobek | Vice President, Accounting | 32,270 |
| William Go | Chief Medical Officer | 44,000 |
| Charles M. Winter | Chief Technical Officer | 77,721 |
| Thomas DiRaimondo | Chief Scientific Officer | 155,825 |
| Zachariah McIver | Chief Medical Officer | 23,286 |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 |
| Byron Robinson | Chief Strategy Officer | 28,000 |
| Ronald W. Barrett | Director | 11,750 |
| Natasha Hernday | Director | 15,481 |
| Jake Simson | Director | 11,750 |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | 9,317,246 |
| Ra Capital Management, L.P. | Director | 2,500 |
| RA Capital Nexus Fund II, L.P. | Director | 11,750 |
| Eric Dobmeier | Director | 15,481 |
| Winston Kung | Director | 11,750 |
| Vickie L. Capps | Director | 79,598 |
| Capital Healthcare Fund LP RA | Director | 6,250 |
| Alana B. McNulty | Director | 6,250 |
| Sheila Gujrathi | Director | 118,889 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Campbell | $13.51M | -$17.75M | $4.61M | $105 | $135 |
| FY2024 David Campbell | $8.97M | $55.19M | $5.05M | $407 | $102 |
| FY2023 David Campbell | $4.19M | $1.05M | $1.67M | $81 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 109 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 20, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 11, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 9, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |